448 related articles for article (PubMed ID: 30326371)
1. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
2. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
[TBL] [Abstract][Full Text] [Related]
3. A novel inhibitor L755507 efficiently blocks c-Myc-MAX heterodimerization and induces apoptosis in cancer cells.
Singh A; Kumar A; Kumar P; Nayak N; Bhardwaj T; Giri R; Garg N
J Biol Chem; 2021 Jul; 297(1):100903. PubMed ID: 34157284
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches.
Carabet LA; Rennie PS; Cherkasov A
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597997
[TBL] [Abstract][Full Text] [Related]
5. Discovery of the first chemical tools to regulate MKK3-mediated MYC activation in cancer.
Yang X; Fan D; Troha AH; Ahn HM; Qian K; Liang B; Du Y; Fu H; Ivanov AA
Bioorg Med Chem; 2021 Sep; 45():116324. PubMed ID: 34333394
[TBL] [Abstract][Full Text] [Related]
6. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
[TBL] [Abstract][Full Text] [Related]
7. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer.
Ton AT; Foo J; Singh K; Lee J; Kalyta A; Morin H; Perez C; Ban F; Leblanc E; Lallous N; Cherkasov A
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269731
[TBL] [Abstract][Full Text] [Related]
8. Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function.
Jiang H; Bower KE; Beuscher AE; Zhou B; Bobkov AA; Olson AJ; Vogt PK
Mol Pharmacol; 2009 Sep; 76(3):491-502. PubMed ID: 19498040
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule modulators of c-Myc/Max and Max/Max interactions.
Berg T
Curr Top Microbiol Immunol; 2011; 348():139-49. PubMed ID: 20680803
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest.
Jeong KC; Ahn KO; Yang CH
Mol Biosyst; 2010 Aug; 6(8):1503-9. PubMed ID: 20485733
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
Butler MS; Roshan-Moniri M; Hsing M; Lau D; Kim A; Yen P; Mroczek M; Nouri M; Lien S; Axerio-Cilies P; Dalal K; Yau C; Ghaidi F; Guo Y; Yamazaki T; Lawn S; Gleave ME; Gregory-Evans CY; McIntosh LP; Cox ME; Rennie PS; Cherkasov A
Oncotarget; 2017 Jun; 8(26):42438-42454. PubMed ID: 28465491
[TBL] [Abstract][Full Text] [Related]
12. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening.
Enyedy IJ; Ling Y; Nacro K; Tomita Y; Wu X; Cao Y; Guo R; Li B; Zhu X; Huang Y; Long YQ; Roller PP; Yang D; Wang S
J Med Chem; 2001 Dec; 44(25):4313-24. PubMed ID: 11728179
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells.
Napoli S; Negri U; Arcamone F; Capobianco ML; Carbone GM; Catapano CV
Nucleic Acids Res; 2006; 34(2):734-44. PubMed ID: 16449206
[TBL] [Abstract][Full Text] [Related]
15. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
16. Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
Wang H; Teriete P; Hu A; Raveendra-Panickar D; Pendelton K; Lazo JS; Eiseman J; Holien T; Misund K; Oliynyk G; Arsenian-Henriksson M; Cosford ND; Sundan A; Prochownik EV
Oncotarget; 2015 Oct; 6(32):32380-95. PubMed ID: 26474287
[TBL] [Abstract][Full Text] [Related]
17. Discovery of an Orally Efficacious MYC Inhibitor for Liver Cancer Using a GNMT-Based High-Throughput Screening System and Structure-Activity Relationship Analysis.
Kant R; Yang MH; Tseng CH; Yen CH; Li WY; Tyan YC; Chen M; Tzeng CC; Chen WC; You K; Wang WC; Chen YL; Chen YA
J Med Chem; 2021 Jul; 64(13):8992-9009. PubMed ID: 34132534
[TBL] [Abstract][Full Text] [Related]
18. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.
Wang J; Ma X; Jones HM; Chan LL; Song F; Zhang W; Bae-Jump VL; Zhou C
J Transl Med; 2014 Aug; 12():226. PubMed ID: 25143136
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma.
Yao R; Xie Y; Sun X; Zhang M; Zhou J; Liu L; Gao J; Xu K
Drug Des Devel Ther; 2020; 14():3983-3993. PubMed ID: 33061303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
